Thailand

Generally, clinicians use brief, validated cognitive screening instruments only when there is suspected cognitive decline. National and society guidance emphasise standardised use of these tools in clinical settings, mostly the Thai versions of the Mini-Mental State Examination (MMSE-Thai) and the Montreal Cognitive Assessment (MoCA-Thai) are routine. Recent work has validated electronic MoCA-Thai (eMoCA-Thai) and app-based screening tools, and machine-learning analyses support MoCA-Thai performance.

Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) are widely available at many public referral hospitals and private centres across Thailand. More advanced imaging, such as amyloid-PET (including tracers such as PiB, florbetapir, florbetaben), is available in specialist centres in Bangkok, like Siriraj Hospital, but used mostly for complex cases or research. The Thai national practice guidelines for nuclear medicine in dementia, developed jointly by the Nuclear Medicine Society of Thailand, the Neurological Society of Thailand, and the Thai Medical Physicist Society, recommend the judicious and evidence-based use of PET and single-photon emission computed tomography (SPECT) imaging to support clinical diagnosis of neurocognitive disorders. The guidelines emphasise selecting the most appropriate imaging modality based on the suspected dementia type, integrating molecular imaging with clinical and structural findings, and ensuring that nuclear medicine specialists follow standardised protocols for image acquisition, interpretation, and reporting. Given Thailand’s limited access to advanced imaging and high costs, the guidance prioritises efficient resource use, advocating for targeted application of PET or SPECT in complex or uncertain cases to enhance diagnostic accuracy, differentiate dementia subtypes, and guide personalised treatment planning.

In Thailand, genetic testing is not yet a standard component of dementia diagnosis and remains primarily limited to research settings or private laboratories. Clinical testing for common risk genes such as APOE ε4, or for rare monogenic forms of AD and dementia, is available in private clinics and hospitals. The cost, lack of insurance coverage, and limited local laboratory infrastructure constrain routine adoption. Current Thai medical practice instead prioritises clinical and neuroimaging evaluation, with genetic analysis reserved for early-onset or atypical presentations, strong family histories, or research participation. Recent studies have begun to explore regional APOE allele frequency and its correlation with cognitive decline, but integration of these findings into clinical decision-making remains in the early stages.

Thailand has made measurable progress in biomarker-based dementia diagnostics, particularly at tertiary and research hospitals in Bangkok such as Siriraj, Ramathibodi, and Chulalongkorn. These centres routinely perform cerebrospinal fluid (CSF) analyses for Aβ42/40 ratios, total-tau, and phosphorylated-tau (p-tau). A recent Thai study using data-driven CSF cut-offs found that adding Aβ42 and p-tau/Aβ42 ratio results to routine work-ups led to a reclassification of about 18% of dementia cases, highlighting how CSF biomarkers can sharpen differentiation between AD and non-AD dementias. However, biomarker access remains largely confined to major urban centres, with limited laboratory capacity and cost barriers preventing widespread clinical use. The 2024 Thai meta-analysis shows that blood-based phosphorylated tau measured via SIMOA is a highly effective Alzheimer’s diagnostic marker, with pooled sensitivity and specificity above 80% and AUC values approaching 0.9, outperforming blood amyloid-beta and total tau and offering a practical, accurate, and less invasive alternative to traditional CSF and PET diagnostics.

Another 2024 Thai multicentre study demonstrated that incorporating Bayes’ theorem into the interpretation of plasma p-tau217 markedly improves diagnostic accuracy for Alzheimer’s disease in real-world memory clinics. By integrating pre-test clinical probability with individualised likelihood ratios, the Bayesian method outperformed both p-tau217 alone and conventional logistic models, achieving an AUC of 0.98 and enabling confident diagnosis or exclusion of AD without confirmatory PET or CSF in most patients. This approach provides a practical, high-performing pathway for low- and middle-income settings, showing that Bayesian-guided plasma biomarkers can significantly reduce reliance on costly or invasive tests while maintaining strong clinical accuracy. These efforts align with regional initiatives like the Southeast Asia Dementia Research Network, which aims to standardise biomarker protocols and expand diagnostic accessibility across Southeast Asia.

In metropolitan areas such as Bangkok and other major Thai cities like Chiang Mai, Khon Kaen, or Songkhla, patients often start with a visit to a primary-care physician or directly approach hospital specialists when cognitive problems are suspected. From there, suspected dementia cases are referred to neurology- or psychiatry-led memory services located in university-affiliated and public hospitals such as Siriraj Hospital, Chulalongkorn Hospital, and Ramathibodi Hospital. Sometimes patients diagnosed with dementia or AD also go to private memory clinics like Bumrungrad International Hospital and Bangkok Hospital. At the same time, some studies suggest that most Thai people with dementia are diagnosed only at moderate disease stages, when behavioural and emotional symptoms become apparent to caregivers. According to a qualitative study conducted in 2016 and 2017, only about one in six older adults with dementia are formally diagnosed and referred to tertiary care, while 72% remain untreated and 45% lack access to rehabilitation or protection services, largely due to limited dementia knowledge among caregivers and primary-care providers.

According to the VivoCare 2025 Review, Thailand has rapidly emerged as a regional leader in dementia and memory care, offering high-quality, person-centred facilities that cater both to Thai citizens and a growing expatriate population seeking affordable long-term care (LTC). The country’s most reputable centres are concentrated in Chiang Mai, Hua Hin, and Bangkok, combining advanced clinical management with a holistic and therapeutic environment. Facilities such as VivoCare (Chiang Mai and Hua Hin) specialise exclusively in dementia and neurodegenerative disorders, providing individualised treatment plans, continuous nursing supervision, and multilingual staff trained in behavioural management. Similarly, Care Resort Chiang Mai and Baan Lalisa feature dedicated memory-care units with high caregiver-to-resident ratios and structured non-pharmacological programmes, designed to support residents with Alzheimer’s disease and related conditions through tailored activities, sensory engagement, and family-inclusive care models.

Complementing these specialised homes are hybrid senior-living models like Vivobene Village and Ban Sabai Village Senior Residence, which combine resort-style living with adaptable levels of care that can transition from independent or assisted living to full dementia support as cognitive needs evolve. Meanwhile, Golden Years Hospital in Bangkok represents a more clinical approach, functioning as a geriatric hospital and long-term care centre suited for patients with advanced dementia requiring medical oversight.

At the community level, significant progress has been achieved since 2016 through the National Health Security Office (NHSO) and its community-based LTC model, which integrates home-based services, trained caregivers, and rehabilitation support into local health networks. This model, piloted in Chiang Mai, Khon Kaen, and Ubon Ratchathani, has expanded nationwide and includes community nurses, care managers, and volunteers who coordinate support for dependent older persons, including those with dementia. At the same time, palliative care has been integrated into Thailand’s National Service Plan and continues to expand through both hospital-based and community models, supported by the Ministry of Public Health and donors such as the Asian Development Bank (ADB).

Under Thailand’s universal health system, outpatient visits, diagnostic evaluations, and prescription of essential drugs such as donepezil or memantine are covered within the benefit structure of the relevant insurance scheme—UCS, SSS, or CSMBS—each with distinct formularies and referral rules. UCS beneficiaries typically access dementia care through provincial or regional hospitals, where generic formulations are provided at low or no direct cost. However, private clinics, imported medications, and branded formulations remain out-of-pocket expenses. For advanced imaging (e.g., MRI, PET) and biomarker analyses, full reimbursement is uncommon, and patients must often pay privately. Recent Thai studies confirm that out-of-pocket expenditure rises sharply with dementia severity, and informal caregiving costs dominate total spending.

In private memory clinics, the cost of care and hospice services typically ranges from 2,800 to 3,600 USD for comprehensive dementia care, substantially lower than equivalent Western services.

A 2020 cross-sectional survey of 140 households showed that the average annual cost per person with dementia was 2,629 USD, with 95% of expenses linked to non-medical care, including 30% attributed to unpaid caregiving time of family members. Most patients lived in low-income households, and care was largely provided by relatives, reflecting dementia’s heavy social and economic impact on families rather than the formal healthcare system. The study concludes that informal caregiving represents the largest component of dementia-related costs in rural Thailand and recommends that policymakers develop subsidies or financial support schemes for families based on dependency levels to mitigate this growing economic strain.

While Thailand has no dementia-specific caregiver allowance, the government provides a universal old-age allowance and funds community-based LTC services through the NHSO. This system includes care managers, trained local caregivers, home-modification grants, and rehabilitation support for dependent elderly, indirectly benefiting dementia families. Local governments and primary healthcare facilities often coordinate these efforts with Village Health Volunteers (VHVs) and community health nurses (CHNs) to provide basic care and education for family caregivers.

In addition, NGOs like the Alzheimer’s and Related Disorders Association of Thailand (ARDA) conduct community education and psychological education programmes for family caregivers. Despite this, coverage remains uneven, as urban caregivers benefit from hospital-linked networks, whereas rural families face limited formal support and rely heavily on informal caregiving. Government and academic experts have recommended expanding caregiver training, respite services, and psychosocial support programmes to reduce this disparity.

In 2017, Thailand’s Ministry of Public Health launched the Thailand Strategic Plan on Dementia (2017–2026). The plan contains six core objectives:

Develop and manage national public-policy mechanisms for dementia.
Raise public awareness, improve understanding of dementia prevention, reduce risk, and promote dementia-friendly communities.
Build an integrated, comprehensive, and accessible social-service system tailored to Thailand’s context.
Strengthen the capacity of families and caregivers through multisectoral participation.
Develop robust data and information systems for dementia monitoring and planning.
Promote research and innovation grounded in Thai contexts, needs, and cultural knowledge.

However, broader strategic direction is also driven by high-level plans such as the 20-Year National Strategic Plan for Public Health (2018–2036), the 12th National Economic and Social Development Plan (2017–2036), and the Second National Plan on the Elderly (2002–2021, revised 2009), which collectively emphasise dignity, autonomy, and social inclusion for older adults. Key priorities include raising public awareness, improving healthcare capacity, and establishing a more sustainable long-term care system.

The broader institutional response to population ageing is defined by the Act on Older Persons (2003) and the National Agenda on an Aged Society (2018), implemented jointly by the Ministry of Social Development and Human Security (MSDHS) and the Ministry of Public Health (MoPH). The National Agenda on an Aged Society has introduced two major reform clusters. The first comprises “6S” measures, which cover social welfare, elder employment, health-system adaptation, safe housing, community “time bank,” and intergenerational education. The second comprises “4C” reforms, which deal with the recognition of ageing as a national priority, revision of employment and care laws, integration of data systems, and innovation for social equity.

Thailand is actively moving toward a more defined national response to dementia through the referenced Thailand Strategic Plan on Dementia. The plan emphasises raising public awareness, strengthening early diagnosis services, enhancing LTC services in the community, building workforce capacity with care managers and caregivers, supporting family caregivers, and promoting research and innovation in dementia care. Implementation is still in progress, since Thailand is integrating dementia more fully into its broader ageing, health-promotion, and LTC frameworks rather than finalizing a separate legislative dementia act.

Since January 2023, the Ministry of Public Health of Thailand has started implementing ICOPE guidelines nationwide. Accordingly, the geriatric clinic in the community hospital will be a key player in the service system. The elder care pathway begins with a nine-domain intrinsic capacity screening, adapted from ICOPE guidance. Those who fail the screening will be sent to the geriatric clinic for management and treatment and will finally have an individual care plan to follow up when they return home. For the monitoring process, dementia becomes one of the community geriatric Key Performance Indicators, with at least 40% of older people who fail the test required to be treated in the clinic. As of now, about five million ageing individuals have been screened.

Since the introduction of the LTC Model in 2016, Thailand has prioritised the training of care managers, community caregivers, and family volunteers, alongside the creation of a digital LTC data system for registration, monitoring, and reimbursement. Institutional steps include training programs for care managers and community caregivers, development of digital LTC registration and monitoring systems, and pilot models of dementia-inclusive community care.

Thai research teams have increasingly adopted and validated novel technological and methodological approaches tailored to their healthcare context. For example, app-based screening tools, such as a Thai-language version of the Montreal Cognitive Assessment (eMoCA-Thai), have been developed to facilitate early detection of cognitive impairment in community-dwelling older adults. This initiative is also aligned with broader efforts in digital and low-cost screening in middle-income countries. In parallel, Thai neurologists and nuclear medicine specialists collaboratively drafted the national guideline, “Thai Guideline for Nuclear Medicine Investigations of Neurocognitive Disorders,” which defines when and how molecular imaging (such as PET and SPECT) should be applied in dementia diagnostics, given local constraints in access and cost.